Bashey 2014.

Methods	This is a multicentre, open‐label, randomised, phase I/II study evaluating the safety and efficacy of low‐dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low‐dose TSEBT monotherapy in patients with mycosis fungoides.
Participants	Inclusion criteria Biopsy‐confirmed mycosis fungoides (MF); clinical stage IB; IIA; IIB; or IIIB Patients must have failed or have been intolerant to at least one prior systemic or skin‐directed therapy 18 years of age or older Required washout period for prior therapies depending on treatment modality Exclusion criteria Prior courses of TSEBT (localised skin‐directed radiotherapy is allowed if administered at least 4 weeks prior to initiation on study) Concomitant use of any anti‐cancer therapy or immune modifier Prior allogeneic or autologous transplant Proven or suspected stage IV disease including patients with B2 (Sezary syndrome); N3 (frank LN disease); or M1 (visceral disease) categories
Interventions	Arm I: TSEBT & Vorinostat Arm II: TSEBT only
Outcomes	Primary outcome Complete clinical response (CCR) at week 8 Secondary outcome Safety and tolerability Clinical response rate (CRR) Duration of clinical benefit
Notes	Additional information was sought but we received no answer.